Opioid Use Disorder (OUD) Treatment and Harm Reduction Training Using AR (Augmented Reality) Technology

使用 AR（增强现实）技术进行阿片类药物使用障碍 (OUD) 治疗和减害培训

• 批准号: 10428673
• 负责人: DOUGLAS NELSON
• 金额: $ 94.84万
• 依托单位: LUMIS CORP.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-15 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10428673
• 关键词: Accident and Emergency department; Adoption; Attitude; Augmented Reality; Basic Life Support; Benchmarking; COVID-19 pandemic; Cardiopulmonary Resuscitation; Caregivers; Cellular Phone; Cessation of life; Clinic; Clinical; Collaborations; Communities; Complex; Computer software; Credentialing; Data; Development; Devices; Disease; Drug usage; Drug user; Ecosystem; Education; Educational Curriculum; Effectiveness; Emergency Medical Technicians; Epidemic; Equipment; Family member; Feasibility Studies; Feedback; Florida; Focus Groups; Goals; Harm Reduction; Health; Health Personnel; Health Professional; Healthcare; Hospital Departments; Immersion; Knowledge; Manikins; Marketing; Maryland; Measures; Medicine; Mission; Modality; Naloxone; National Institute of Drug Abuse; New Hampshire; Nursing Schools; Ohio; Opioid; Overdose; Paramedical Personnel; Participant; Patients; Pennsylvania; Peripheral; Persons; Pharmaceutical Preparations; Pharmacotherapy; Pharmacy facility; Phase; Process; Professional Organizations; Provider; Recommendation; Reporting; Research; Research Design; Research Methodology; Resources; Site; Small Business Innovation Research Grant; Substance Use Disorder; System; Tablets; Technology; Testing; Time; Training; Training Support; Treatment outcome; United States; Universities; West Virginia; base; college; commercialization; cost; design; effectiveness validation; efficacy evaluation; efficacy validation; experience; implementation protocol; improved; improved outcome; insight; instrument; knowledge base; medical schools; operation; opioid overdose; opioid use disorder; overdose death; overdose education; pilot test; prescription opioid; programs; prototype; recruit; response; simulation; success; synthetic opioid; treatment services; usability; virtual experiments

Over the last decade, drug overdose death has created an epidemic across the United States. In 2018, there were 67,367 drug overdose deaths—a decrease of about 4.6% from 2017—but almost 70% of the deaths involved opioids. While overdoses related to prescription opioids have decreased, synthetic opioids made up over two-thirds of all opioid-related overdose deaths in 2018. West Virginia, Maryland, Pennsylvania, Ohio, and New Hampshire had the highest rates of drug overdose deaths in 2018. Furthermore, there are reported increases in overdose deaths that may result from isolation and access to drugs and treatment services related to the COVID-19 pandemic. The goal of this proposal is closely aligned with the mission of the National Institute on Drug Abuse (NIDA) to educate clinical providers and lay people on improving treatment and outcomes for those suffering from substance use disorders (SUDs), specifically in response to drug overdose. Many barriers have been identified for training providers on SUDs. Simulation-based training has shown promise for training providers about responding to drug overdose during Basic Life Support (BLS) training. However, simulation-based training is usually resource intensive and can be difficult to implement as current simulator technologies require facilities, staff, and technology support. Overdose education and naloxone distribution (OEND) is associated with improved outcomes for people experiencing opioid overdose as well as decreased drug use by people who participated in OEND programs. Increasing access to OEND could expand these positive results. This Phase II SBIR aims to further develop Lumis’s Augmented Reality Training on Overdose (ART-OD) within Lumis’s existing healthcare training simulator, the InSight Platform. The InSight Platform incorporates knowledge-based and hands-on training, requires less resources than traditional simulation, and supports broad deployment. The ART-OD prototype developed in Phase I met all benchmarks for success, including: (1) development and integration of an ART-OD prototype into the InSight Platform, (2) increased knowledge and attitudes towards recognizing and responding to an opioid overdose, and (3) positive feedback, usability, and market acceptance from various stakeholders. Mixed methods research will: (1) enhance the design of ART-OD developed in Phase I using an expanded pool of subject matter experts (SMEs) and integration with an existing prototype for training clinicians from the University of Florida College of Medicine (UCF COM), (2) integrating the enhanced design for ART-OD and the UCF COM prototype into an advanced ART-OD product, and (3) conducting pilot testing of ART-OD with potential end-users and stakeholders to validate training effectiveness and market potential.

在过去的十年中，药物过量死亡在美国造成了一种流行病。在2018年， 有67,367例药物过量死亡，比2017年减少了约4.6％，但近70％的死亡人数减少了 涉及阿片类药物。虽然与处方阿片类药物有关 2018年，超过三分之二的阿片类药物相关过量死亡。西弗吉尼亚州，马里兰州，宾夕法尼亚州，俄亥俄州，以及 新罕布什尔州在2018年的药物过量死亡率最高。此外，据报道 与药物和治疗服务有关 到19号大流行。该提案的目标与国家研究所的使命密切相符 关于药物滥用（NIDA），以教育临床提供者，并为改善治疗和结果而培养人员 那些患有药物使用障碍（SUD）的人，特别是针对药物过量的人。 许多障碍已被确定用于SUDS的培训提供者。基于模拟的培训已显示 在基本生命支持（BLS）培训期间对培训提供者的承诺。 但是，基于模拟的培训通常是资源大量的，很难作为当前 模拟器技术需要设施，员工和技术支持。 过量的教育和纳洛酮分布（OEND）与人们的结果改善有关 参加OEND计划的人会经历阿片类药物过量以及减少药物使用。 增加对OEND的访问可以扩大这些积极的结果。 II阶段SBIR旨在进一步开发Lumis对过量用药的增强现实培训（ART-OD） 在Lumis现有的医疗保健培训模拟器中，Insight平台。 Insight平台合并 基于知识和动手培训，比传统模拟需要的资源少，并支持广泛的资源 部署。第一阶段开发的ART-OD原型符合所有成功基准，包括：（1） 将Art-OD原型开发和整合到Insight平台中，（2）知识的增加和 对认识和应对阿片类药物过量的态度，以及（3）积极的反馈，可用性和 各种利益相关者的市场接受。 混合方法研究将：（1）使用一个阶段中增强ART-OD的设计 扩大主题专家（中小企业）的扩展库，并与现有的培训临床医生的现有原型集成 佛罗里达大学医学院（UCF COM），（2）整合Art-OD的增强设计 以及UCF COM原型成一个高级ART-OD产品，（3）使用ART-OD进行试验测试 潜在的最终用户和利益相关者验证培训有效性和市场潜力。